The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | How can botensilimab improve outcomes in colorectal cancer?
Benjamin Schlechter, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the potential of botensilimab, an engineered Fc-enhanced CTLA-4 antibody, in treating colorectal cancer, where conventional checkpoint inhibitors have shown limited efficacy. Botensilimab aims to enhance antigen-presenting cell activity and clear regulatory T-cells, improving immune response activation in the dense immune-suppressive environment of colon and rectal cancer. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
